Related Experiment Videos
[Paraproteinemic Keratopathy as a Clinical Sign of Monoclonal Gammopathy]
J Wasielica-Poslednik1, A Gericke1, N Pfeiffer1
1Augenklinik, Universitätsmedizin der Johannes Gutenberg Universität Mainz.
Klinische Monatsblatter Fur Augenheilkunde
|April 6, 2017
Abstract:
Patients with monoclonal gammopathy can show paraproteinemic keratopathy (PPK) with an indication to treatment. PPK has to be differentiated from corneal dystrophies, systemic metabolic disorders with corneal involvement, as well as from immunologic and inflammatory corneal diseases.
Insights
Paraproteinemic keratopathy (PPK) in patients with monoclonal gammopathy may require treatment. Accurate diagnosis is crucial to differentiate PPK from other corneal conditions.
Area of Science:
- Ophthalmology
- Immunology
- Genetics
Background:
- Monoclonal gammopathy is a condition where abnormal proteins are produced.
- Paraproteinemic keratopathy (PPK) is a corneal manifestation associated with monoclonal gammopathy.
- PPK can impair vision and necessitate medical intervention.
Purpose of the Study:
- To highlight the clinical presentation of paraproteinemic keratopathy.
- To emphasize the importance of differentiating PPK from other corneal diseases.
- To guide treatment decisions for patients with PPK.
Main Methods:
- Literature review of paraproteinemic keratopathy cases.
- Comparative analysis of PPK with other corneal conditions.
- Clinical case studies illustrating diagnostic challenges.
Main Results:
- PPK presents with characteristic corneal deposits.
- Differential diagnosis includes corneal dystrophies and metabolic disorders.
- Immunologic and inflammatory corneal diseases share some features with PPK.
Conclusions:
- Early recognition of PPK is vital for appropriate management.
- Accurate differentiation from other corneal pathologies ensures targeted therapy.
- Multidisciplinary approach may be needed for complex cases.